Quotient Investment in its Allan-Robb Campus: Nominated for Scotland’s Life Sciences Awards
The organisers of Scotland’s Life Sciences Awards have shortlisted Quotient for the “Investment of the Year” category. The nomination recognises Quotient’s GBP 27m investment in its Allan-Robb Campus – a state-of-the-art R&D and manufacturing facility situated on the Scottish Enterprise Biocampus just outside Edinburgh in Scotland.
“Though we did not win the award, we are honoured to have been shortlisted in the investment category of the 2018 Scotland’s Life Sciences Awards. This nomination is a testament to the importance of continuing investments in the life sciences sector here in Scotland,” said John Allan, Executive Vice President and Chief Technology Officer at Quotient.
“This nomination also recognises the importance of Scotland in Quotient’s long-term commitment to the global transfusion diagnostics market. After all, our company’s roots can be traced back to its beginnings in the Scottish National Blood Transfusion Service. From those roots, we have grown into a 400-strong company with operations in Scotland, Switzerland and the United States,” said Jeremy Stackawitz, President at Quotient.
(L-R) Susan Galloway (Head of Product Support), Paul Cowan (Quotient Founder), Franz Walt (Interim CEO), HRH Princess Anne
The Allan-Robb Campus, Quotient’s new custom-designed facility, was officially inaugurated by HRH The Princess Royal on 10 April 2018. The inauguration of this facility marks a significant milestone in Quotient’s history, enabling it to increase capacity in line with its growth plans, while improving manufacturing efficiency. The Allan-Robb Campus provides some 150 jobs ranging from research and development to manufacturing, management and administration. In 2017, this team obtained FDA licensing for 17 new transfusion reagents that will now be sold in the US market.
The Allan-Robb Campus is also home for some 50 scientists working on the development of Quotient’s ground-breaking MosaiQTM transfusion diagnostics system. It has been designed to deliver fast, comprehensive antigen typing, antibody detection and disease screening results. When launched, it has the potential to transform transfusion diagnostics by increasing efficiencies in the lab, while improving patient outcomes.
“We’re honoured to have been on the shortlist with some of Scotland’s most renowned life sciences companies,” said Mr Allan.
To learn more about the Allan-Robb Campus, read the media release.